title: Eosinophilic gastroenteritis in a young girl--long term remission under Montelukast.
abstract: BACKGROUND
  Eosinophilic gastrointestinal disorders are an emerging disease entity characterized by eosinophilic infiltration of the intestinal wall. Oral steroids can be still considered as first line treatment. Unfortunately relapses are quite common. Usually long term low-dose prednisone or immunosuppressive therapy is required, which is especially problematic in young patients. Thus a reliable steroid sparing agent with low side effects suitable for long term use is needed. There are strong hints to a similar pathophysiology of eosinophilic gastrointestinal disorders to that of asthma. Indeed leukotriene D4 plays an important role in the recruitment of eosinophils into the intestinal tissue causing damage. This patho-mechanism provides the rationale for the treatment with a leukotriene D4 receptor antagonist. Recently there have been first reports about successful short term use of Montelukast in eosinophilic gastrointestinal disorders.
  
  
  METHODS
  We report the case of a 17 year old girl with a long history of severe abdominal complaints leading to several hospitalizations in the past. Mimicking the picture of an intestinal tuberculosis she received an anti mycobacterial treatment without any success. Marked eosinophilia in blood, ascites and tissue samples of the intestinal tract finally lead to the diagnosis eosinophilic gastroenteritis. Tapering off prednisone caused another severe episode of abdominal pain. At that point leukotriene antagonist Montelukast was started at a dose of 10 mg once daily. Steroids could be tapered off completely within six weeks. The patient has been free of symptoms for over two years by now. Routine examinations, blood tests and endoscopy have rendered regular results. So far no side effects were noted.
  
  
  CONCLUSIONS
  Here report about successful long term remission of eosinophilic gastroenteritis under Montelukast. Further randomized control trials are required to asses the full benefits of Montelukast therapy in the whole spectrum of eosinophilic gastrointestinal disorders.
authors: Department of Internal Medicine, Marienhospital, Ruhr University, Herne, Germany. ivo.quack@rub.de
authors: Ivo
authors: I
authors: Quack
authors: Lorenz
authors: L
authors: Sellin
authors: Nikolaus J
authors: NJ
authors: Buchner
authors: Dirk
authors: D
authors: Theegarten
authors: Lars C
authors: LC
authors: Rump
authors: Bernhard F
authors: BF
authors: Henning
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D003521:Cyclopropanes; D004802:Eosinophilia / Q000188:drug therapy*; D005260:Female; D005759:Gastroenteritis / Q000188:drug therapy*; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D012074:Remission Induction; D013440:Sulfides
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast